While several menin inhibitors are in different phases of development with revumenib already US FDA approved in R/R KMT2A-r acute leukemias and more recently NPM1mut AML, ongoing clinical benefits with these agents as monotherapy will be important to evaluate and may turn out to be possibly challenging. This evidence concerns the gene MEN1 and acute leukemia.